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Purpose: Alcohol consumption has decreased in Denmark in recent years. We aimed to 
illustrate and investigate the developments in the incidence, hospital care, and mortality of 
alcohol-related liver disease (ALD) in Denmark during the last 25 years.
Patients and Methods: Through nationwide healthcare registries, we identified all Danish 
patients with incident ALD in 1994–2018. We computed standardized incidence rates by sex, 
age, and geography, age-specific incidence rates by birth cohort, and standardized preva-
lence. We enumerated inpatient admissions, days of admission, outpatient visits, and emer-
gency room visits. Lastly, we estimated relative risks of mortality, standardized mortality 
rates, and the proportion of deaths caused by ALD.
Results: The standardized incidence rate decreased from its peak at 357 per 1,000,000 in 2009 
to 240 per 1,000,000 in 2018, and the decrease was evident for both sexes and all age groups 
below 70 years. The standardized prevalence was stable around 0.22% from 2011 onwards. 
There was an almost fivefold geographic variation in standardized incidence by municipalities, 
and age-specific incidence rates decreased sequentially with each 5-year birth cohort after 1960. 
The number of inpatient admissions, days of admission, and emergency room visits decreased 
during the study period, while the number of outpatient visits was stable. For patients diagnosed 
in 2014–2018 compared to 1994–1998, the relative risk of 1-year mortality was 0.83 (95% 
confidence interval: 0.78–0.87), and the standardized mortality along with the proportion of 
deaths caused by ALD decreased during the study period.
Conclusion: The incidence of ALD decreased from 357 to 240 per 1,000,000 over the last 
10 years in Denmark. During the same period, the prevalence remained stable around 0.22% 
and mortality decreased. Additionally, the burden of ALD on hospital care decreased 
significantly between 1994 and 2018. We anticipate a further decrease in the incidence of 
ALD in the future.
Keywords: alcohol-related liver disease, epidemiology, time trends, public health, incidence, 
healthcare, mortality, cause of death
Plain Language Summary
We studied the epidemiology of alcohol-related liver disease in Denmark from 1994 to 2018. 
During this 25-year period, the annual number of Danes diagnosed with alcohol-related liver 
disease has decreased. Meanwhile, the prognosis for Danish patients with alcohol-related 
liver disease has improved: patients have fewer hospital admissions and live longer.
Introduction
Alcohol-related liver disease (ALD) encompasses any liver injury caused by alco-
hol, from simple steatosis to cirrhosis.1 Though alcohol-attributable mortality has 
come down in Denmark in recent years, it remains high compared to other Nordic 
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countries.2 The global burden of ALD is substantial,3 and 
in Denmark in 2017, 10% of disability-adjusted life-years 
(DALYs) lost were attributable to alcohol use.4 The rela-
tionship between alcohol consumption and liver injury is 
dose-dependent,5 but factors such as daily drinking, drink-
ing outside meals, and obesity also affect individual-level 
risk.6–8 At the population level, the incidence of ALD is 
closely linked with alcohol consumption.9 Therefore, gov-
ernments may reduce the burden of ALD by increasing 
alcohol taxation and reducing availability, and by imple-
menting screening and brief interventions for harmful 
alcohol use in primary care.9,10
We have previously studied the epidemiology of ALD 
in Denmark in 1988–2013.11,12 In those studies, we saw 
a stable incidence, but predicted a future decrease in the 
incidence of ALD based on birth cohort analyses.11,12 
Moreover, per capita alcohol consumption has come 
down since our last study.13
With this registry-based study, we aimed to illustrate 
and investigate the developments in the incidence, hospital 
care, and mortality of ALD in Denmark from 1994 
through 2018. Such measures are valuable in guiding 
alcohol prevention strategies and monitoring public health.
Patients and Methods
Setting
This nationwide, registry-based cohort study was conducted 
in the Danish population of 5,781,190 people 
(1 January 2018). In Denmark, citizens are provided tax- 
supported, universal health care, which grants equal access 
to general practitioners and hospitals. All Danish citizens are 
issued a personal identification number at birth or immigra-
tion, which allows linkage across all national registries. The 
Danish National Patient Registry was established in 1977. It 
contains data from all inpatient hospitalizations including 
primary and secondary discharge diagnosis codes as well as 
procedure codes going back to 1977. Outpatient visits are 
registered from 1994 onwards, and emergency room visits 
are registered from 1995 onwards.14,15 The Danish Civil 
Registration System records vital status with complete fol-
low-up from birth or immigration until death or emigration,14 
and the Danish Register of Causes of Death records immedi-
ate, supplementary, and underlying causes of death.16
Study Population
We identified all Danish patients with a first diagnosis of 
ALD from 1977 to 2018 in the Danish National Patient 
Registry using the diagnosis codes for cirrhosis due to 
alcohol-related liver disease (ALD cirrhosis) (ICD-8: 
571.09, ICD-10: K70.2, K70.3, and K70.4), alcoholic 
hepatitis (ICD-10: K70.1), steatosis due to alcohol- 
related liver disease (ALD steatosis) (ICD-8: 571.10, 
ICD-10: K70.0), and unspecified ALD (ICD-10: K70.9). 
If, at that time, the patient received diagnosis codes for 
more than one of these conditions, we used the following 
hierarchy: cirrhosis, hepatitis, steatosis, unspecified. We 
limited the study period to 1994–2018 (the ICD-10 era) 
to ensure homogeneity of coding practice.15 We used data 
from 1977–1993 to avoid misclassifying patients with 
prevalent ALD as patients with incident ALD, and we 
used data from 2019 on vital status to add an additional 
calendar year of follow-up. In the analysis of emergency 
room visits, the study period was limited to 1995–2018. 
We defined ALD-related mortality as either of the follow-
ing underlying causes registered in the Register of Causes 
of Death: liver cirrhosis (ICD-10: K74.x), ALD (ICD-10: 
K70.x), alcohol misuse (ICD-10: F10.x), and hepatocellu-
lar carcinoma (ICD-10: C22.x).
Statistical Analysis
For each year, we computed the incidence rate as the 
number of patients with a first-time ALD diagnosis during 
the year divided by the number of Danish citizens at the 
beginning of the same year. We used direct standardization 
to adjust the annual incidence rates for changes in the sex- 
and age group-distribution of the Danish population using 
the Danish population on 1 January 2018 as the standard 
(Supplementary Table S1). In this manner, we computed 
overall and stratum-specific standardized incidence rates 
by sex and age group (<40, 40–49, 50–59, 60–69, ≥70). To 
analyse the geographic distribution of ALD, we computed 
mean annual incidence rates of ALD for each of the 98 
Danish municipalities during the last 10 years (2009–-
2018). We then standardized these rates to the sex- and 
age group-distribution of the entire Danish population on 
1 January 2018 using direct standardization 
(Supplementary Table S1). Moreover, to compare the age- 
specific incidence rates across birth cohorts, we computed 
incidence rates by 5-year birth cohorts born between 1930 
and 1979 and 5-year age groups from 30 to 79 years. We 
used age to estimate the distribution of birth years. For 
instance, the number of people born in 1960–1964 and 
alive at age 40–44 was approximated as the number of 
people aged 40–44 in year 2000–2004.
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We computed overall and sex-specific prevalence by 
dividing the number of patients with ALD on 1 January of 
a given year with the Danish population on the same day. 
We then standardized to the sex- and age-distribution of 
the Danish population on 1 January 2018 using direct 
standardization.
The number of inpatient admissions per patient with 
ALD each year was estimated as the number of all-cause 
inpatient admissions (excluding transfers between hospital 
departments) divided by the person-years at risk in a given 
calendar year. Similarly, we estimated the number of 
ALD-related outpatient visits and all-cause emergency 
room visits per person-year at risk. ALD-related outpatient 
visits were defined as any of the following: outpatient 
visits with diagnosis codes for ALD (including alcohol- 
related hepatic encephalopathy) (ICD-10: K70, ICD-8: 
571.09 or 571.10), ascites (ICD-10: R18.x), or esophageal 
or gastric varices (ICD-10: I85.x and I86.4) or procedure 
codes for banding of or sclerotherapy for esophageal 
varices (NCSP: JCA20, JCA22 and JCA32) or diagnostic 
or therapeutic paracentesis (NCSP: TJA10.x) in patients 
with ALD. For every year, we also estimated the total 
number of days spent in hospital as an inpatient per per-
son-year and the average length of admission. The route of 
diagnosis was defined as either emergent (during emer-
gency room visit or at emergent inpatient admission) or 
elective (during outpatient visit or at elective admission) 
dependent on where the patient received their first primary 
diagnosis code for ALD.
We do not report confidence intervals in the analyses of 
incidence, prevalence, and hospital care since these ana-
lyses are enumerations of complete data and not statistical 
estimates. Hence, there is no statistical uncertainty to 
account for in these analyses.17
We used the Kaplan-Meier method to estimate crude 
all-cause mortality with respect to time since first ALD 
diagnosis by sex, age group, ALD diagnosis, and calendar 
time period. We further estimated relative risks (RR) of 1- 
and 5-year all-cause mortality by sex (female [reference], 
male), age group (<40 years [reference], 40–59 years, 
60–69 years, >70 years), ALD diagnosis (steatosis [refer-
ence], unspecified, hepatitis, cirrhosis), and calendar time 
period (1994–1998 [reference], 1999–2003, 2004–2008, 
2009–2013, 2014–2018) by generating pseudo- 
observations to fit a generalized linear model.18 Within 
each stratum we adjusted the RRs for confounding by 
the other covariates, so the effect of one covariate (eg 
sex) on all-cause mortality was adjusted for differences 
in the other three covariates (eg age group, ALD diagno-
sis, and calendar time period). To increase the comparabil-
ity of calendar time periods, we made their lengths of 
follow-up equal, so for instance, patients diagnosed with 
ALD in 1994–1998 were censored on 31 December 1999, 
and patients diagnosed in 2014–2018 were censored on 
31 December 2019. To investigate time trends in mortality 
further, we estimated 1-, 3-, and 5-year mortality risk by 
calendar year, sex, age group, and ALD diagnosis using 
the Kaplan-Meier method. We then adjusted for changes in 
the population of patients with ALD over calendar time 
using direct standardization. For each year, we standar-
dized the expected number of deaths in each stratum to the 
distribution of sexes, age groups, and ALD diagnoses of 
patients diagnosed in 2013 (Supplementary Table S2). We 
repeated the analysis of standardized mortality, stratified 
by the route of diagnosis. For each year, we calculated the 
proportion of 1-year mortality that could be attributed to 
ALD among patients with established ALD. This measure 
was chosen to avoid bias by differing follow-up times 
among patients with ALD.
Lastly, to test the extent to which diagnoses of ALD 
steatosis affected the results, we repeated all aforemen-
tioned analyses excluding all diagnoses of ALD steatosis.
External Data
To provide context for our findings, we included survey 
data from 2010, 2013, and 2017 on high-risk alcohol 
consumption from the Danish National Health Surveys.19 
High-risk alcohol consumption is defined as >252/168 
grams per week for men/women by the Danish Health 
Authority. Additionally, we used data collected by 
Statistics Denmark on the yearly sales of pure alcohol 
during the study period. These data cover all domestic 
taxed sales and cross-border trade with alcohol.13
Results
We identified 41,316 Danish patients with a first-time diag-
nosis of ALD between 1994 and 2018. During this period, the 
median age at first diagnosis increased from 52 (interquartile 
range: 45–61) to 62 years (interquartile range: 55–70), and 
the proportion of men was stable around 68%. Overall, 69% 
had ALD cirrhosis at the time of the first ALD diagnosis, 
14% had ALD steatosis, 10% had unspecified ALD, and 7% 
had alcoholic hepatitis. The distribution of diagnoses did not 
change throughout the study period (Supplementary Figure 
S1). During 219,796 person-years of follow-up, 30,393 
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patients died, and the proportion of deaths caused by ALD 
decreased from 76% in 1994 to 60% in 2018.
Incidence and Prevalence
The overall standardized incidence rate (SIR) of ALD 
peaked at 357 per 1,000,000 in 2009. Since then, it 
decreased steadily to 240 per 1,000,000 in 2018, corre-
sponding to a ratio of 0.67 (Figure 1). Each year, the SIR 
was about twice as high for men as for women. For 
women, the SIR decreased from 225 in 2009 to 146 in 
2018 (ratio: 0.65), and for men, it decreased from 491 in 
2009 to 335 in 2018 (ratio: 0.68) (Figure 1). We observed 
a decrease in ALD incidence in both sexes and all age 
groups below 70 years, and the decrease was most pro-
nounced in women aged 40–49 (ratio: 0.32, difference: 
−176 per 1,000,000), women aged 50–59 (ratio: 0.43, 
difference: −363 per 1,000,000), and in men aged 40–49 
(ratio: 0.51, difference: −176 per 1,000,000). There was 
a slight increase in the ALD incidence of women aged 70 
or more (ratio: 1.06, difference: 15 per 1,000,000) (Figure 
2). The overall standardized prevalence of ALD was stable 
around 0.22% since 2011. In 2018, the prevalence of ALD 
was 0.29% in men and 0.16% in women.
We observed large geographic variation between muni-
cipalities. The mean annual SIRs peaked in small island 
communities where we observed the highest rates of 669, 
638, and 570 per 1,000,000. We observed the lowest rates 
of 144, 150, and 155 per 1,000,000 in rural areas in the 
middle of Jutland. Overall, the eastern part of Denmark 
had higher rates than the western part (Figure 3).
Regarding 5-year birth cohorts, the 1950–1959 birth 
cohorts had the highest age-specific incidence rates, and 
the age-specific incidence rates decreased sequentially 
with each following birth cohort (Figure 4 and 
Supplementary Figure S2).
Hospital Care
The number of all-cause inpatient admissions for patients 
with ALD per person-year decreased from 2.05 in 1994 to 
1.54 in 2000, was stable until 2010, and then decreased 
further to 1.12 in 2018 (Figure 5, top left). The total 
number of inpatient days for patients with ALD per per-
son-year decreased from 17.3 in 1994 to 7.1 in 2018 
(Figure 5, top right), and the average length of an inpatient 
admission decreased from 8.4 days in 1994 to 6.3 days in 
2018. The number of ALD-related outpatient visits per 
person-year was around 1 throughout the study period, 
with no apparent time trend (Figure 5, bottom left). The 
number of all-cause emergency room visits for patients 
with ALD per person-year decreased gradually from 2.59 
in 1995 to 0.82 in 2018 (Figure 5, bottom right). In gen-
eral, the rates of hospital care were higher for men than for 
women (Figure 5).
In 1994, the route of diagnosis was emergent in 62% of 
patients and elective in 38% of patients. The elective route 
of diagnosis became the commonest in 2014, and in 2018, 
60% of patients were diagnosed during elective care 
(Supplementary Figure S3).
Mortality
The overall mortality after first ALD diagnosis was 27.5% 
(95% confidence interval [CI]: 27.1–27.9%) after 1 year and 
53.9% (95% CI: 53.4–54.4%) after 5 years. For patients 
diagnosed in 2014–2018 compared to patients diagnosed in 
1994–1998, the adjusted RR was 0.83 (95% CI: 0.78–0.87) for 
1-year mortality and 0.93 (95% CI: 0.90–0.97) for 5-year 
mortality (Table 1). Compared to ALD steatosis, patients 
with ALD cirrhosis had the highest crude mortality risk and 
the highest adjusted RRs of mortality of 3.10 (95% CI: 2.86–-
3.37) after 1 year and 2.00 (95% CI: 1.92–2.09) after 5 years 
(Supplementary Figure S4 and Table 1), and men had higher 
mortality than women with adjusted RRs of 1.18 (95% CI: 
1.14–1.23) for 1-year mortality and 1.13 (95% CI: 1.11–1.15) 
for 5-year mortality. We observed a decrease in 1-, 3-, and 
5-year mortality from 2010 to 2015, after adjustment for the 
effects of sex, age, and ALD diagnosis by standardization 
(Figure 6). This decrease was less pronounced when stratified 
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Figure 1 Time trends in annual standardized incidence rates per 1,000,000 Danish 
population 1994–2018 (left y-axis) and annual alcohol sales per Danish citizen >18 
years in liters of pure alcohol 1994–2018 (right y-axis).
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proportion of 1-year mortality caused by ALD decreased from 
75.8% in 1994 to 60.5% in 2018 (Figure 6).
Sensitivity Analyses
By excluding diagnoses of ALD steatosis from the ana-
lyses, incidence and prevalence measures decreased by 
around a tenth, emergency room visits per patient 
increased by around a tenth, inpatient admissions and out-
patient visits per patient increased by around a third, and 
the proportions of emergent diagnoses and deaths caused 
by ALD were unchanged. None of the observed time 
trends were altered.
Alcohol Consumption
The average annual amount of pure alcohol sold per citi-
zen >18 years decreased by 22.4% from 12.5 liters in 1994 
to 9.7 liters in 2018 (Figure 1). The proportion whose 
alcohol consumption exceeded the high-risk threshold of 
252/168 grams of pure alcohol per week (for men/women) 
decreased from 10.6% in 2010 to 6.9% in 2017 
(Supplementary Figure S4).
Discussion
The incidence of ALD decreased since 2009 in Denmark, 
and the decrease was evident for both sexes and all age 
Age groups


































































































Figure 2 Time trends in annual standardized incidence rates per 1,000,000 Danish population by sex (top/bottom) and age groups (colors).
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Figure 4 Incidence rates of ALD per 1,000,000 Danish population by 5-year birth cohorts from 1930 to 1979 (colors) and 5-year age groups from 30 to 79 years (x-axis).
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groups under 70 years. Within Denmark, there was 
a nearly fivefold geographic variation in ALD incidence. 
We saw a decrease in inpatient admissions, emergency 
room visits, and inpatient days per person-year, while the 
number of outpatient visits and average length of hospita-
lization were stable through 2018. Concurrently, the mor-
tality of patients with ALD decreased, which was reflected 
in a stable prevalence of 0.22%.
It is a strength of this study that we have a single 
nationwide, public healthcare system with a long history 
of recording patients’ diagnoses. On the other hand, reli-
ance on diagnosis codes is our main concern, since code 
validity is paramount to the validity of our findings. The 
codes for liver cirrhosis were validated using medical 
records in 1997 with a positive predictive value (PPV) of 
85.4% and a completeness of 93.2% (n = 198).20 In 2008, 
we found that 78% of patients with a code for ALD 
cirrhosis and available liver biopsy data had biopsies con-
taining incipient or manifest cirrhosis,21 but in clinical 
practice, liver biopsies are restricted to patients with uncer-
tain diagnoses; therefore, the true PPV is likely higher. The 
codes for liver disease in general and had a PPV of 100% 
(n = 100) in a study from 2011,22 and the codes for ALD 






















































































Figure 5 Time trends in hospital care of patients with ALD 1994–2018; the number of all-cause inpatient admissions per patient per person-year (top left). The number of 
total inpatient days per patient per person-year (top right). The number of ALD-related outpatient visits per patient per person-year (bottom left). The number of all-cause 
emergency room visits per patient per person-year (bottom right).
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using a larger sample (n = 1166).23 In that study, however, 
the diagnosis codes had to be verified paraclinically or by 
cirrhosis complications to be considered valid.23 The code 
for alcoholic hepatitis had a PPV of 90% in a study from 
2014 (n = 50).24 The codes for ALD steatosis have not 
previously been validated, and the frequency of their use is 
likely influenced by the degree of clinical ascertainment. 
Therefore, we conducted sensitivity analyses excluding 
codes for ALD steatosis. This did not alter any of the 
observed trends. On top of code validity, we are aware 
that ALD is under-detected at the hospitals. For instance, 
11% of patients with ALD cirrhosis in Denmark are only 
diagnosed at death.25 However, we find it unlikely that the 
observed time trends were influenced by either code valid-
ity or undetected ALD, since coding practices and the 
proportion of undetected ALD have remained stable dur-
ing the ICD-10 era.15
In our previous study, we found a somewhat stable 
ALD incidence, but forecasted a future decrease driven 
by progressively lower incidence rates in the birth cohorts 
born after 1960.11 In this study, we saw a substantial 
incidence-decrease during the years following our last 
study. This finding demonstrates the utility of birth cohort 
analyses in national forecasts. The age-specific incidence 
Table 1 Mortality After First Alcohol-Related Liver Disease Diagnosis
Crude 1-Year 
Mortality, % (95% 
CI)
Crude 5-Year 
Mortality, % (95% 
CI)
Adjusted RR for 1-Year 
Mortality (95% CI) †
Adjusted RR for 5-Year 
Mortality (95% CI) †
Sex
Female 24.3 (23.5–25.0) 49.3 (48.4–50.2) Ref. Ref.
Male 29.0 (28.5–29.5) 56.0 (55.4–56.6) 1.18 (1.14–1.23) 1.13 (1.11–1.15)
Age group
<40 years 14.4 (13.0–15.8) 32.2 (30.3–34.1) Ref. Ref.
40–49 years 20.7 (19.8–21.6) 44.5 (43.5–45.6) 1.30 (1.18–1-44) 1.28 (1.20–1.36)
50–59 years 24.8 (24.1–25.6) 51.7 (50.8–52.5) 1.52 (1.37–1.68) 1.46 (1.38–1.55)
60–69 years 31.3 (30.4–32.1) 59.6 (58.7–60.5) 1.93 (1.75–2.14) 1.68 (1.58–1.79)
>70 years 44.1 (42.8–45.5) 74.8 (73.5–76.1) 2.76 (2.49–3.05) 2.09 (1.96–2.22)
Alcohol-related liver 
disease diagnosis
Steatosis 9.6 (8.9–10.4) 28.5 (27.3–29.7) Ref. Ref.
Unspecified 21.5 (20.3–22.8) 46.0 (44.4–47.6) 2.19 (1.98–2.41) 1.57 (1.49–1.65)
Hepatitis 24.5 (23.0–26.1) 45.9 (44.1–47.7) 2.60 (2.35–2.88) 1.64 (1.56–1.74)
Cirrhosis 32.4 (31.9–33.0) 61.2 (60.6–61.8) 3.10 (2.86–3.37) 2.00 (1.92–2.09)
Calendar time period
1994–1998 25.4 (24.5–26.4) 49.9 (48.8–51.1) Ref. Ref.
1999–2003 26.9 (26.0–27.9) 53.5 (52.4–54.6) 1.00 (0.95–1.05) 1.03 (1.00–1.07)
2004–2008 30.0 (29.0–31.0) 57.3 (56.2–58.3) 1.05 (1.00–1.10) 1.07 (1.03–1.10)
2009–2013 29.0 (28.0–29.9) 55.1 (54.1–56.2) 0.97 (0.93–1.02) 0.99 (0.95–1.02)
2014–2018 25.8 (24.9–26.8) 52.8 (51.3–54.2) 0.83 (0.78–0.87) 0.93 (0.90–0.97)
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Figure 6 Time trends in sex-, age-, and diagnosis-standardized 1-, 3-, and 5-year 
mortality (left y-axis) and the proportion of 1-year mortality caused by ALD (right 
y-axis).
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is still decreasing sequentially by birth cohorts, and thus, 
we anticipate a further reduction in the incidence of ALD 
in Denmark over the coming years. Besides a decreasing 
incidence, another consequence of higher age-specific 
incidence rates in older birth cohorts is an aging ALD- 
population, and the median age at diagnosis indeed 
increased by 10 years during the study period.
Our findings contrast with reports of increasing ALD 
incidence from Finland,26 China,27 and the United 
Kingdom.28 The authors of these reports point to increased 
alcohol consumption as a likely cause. Concordantly, our 
data show that per capita alcohol consumption is corre-
lated with ALD incidence. Hence, the observed decrease 
in ALD incidence is likely caused by a decreased national 
alcohol consumption. Regarding other possible causes, 
there is no evidence suggesting that the decrease in ALD 
incidence is part of a more general trend in liver disease in 
Denmark. Actually, the incidence of autoimmune hepatitis 
has doubled in 1994–2012,29 and metabolic associated 
fatty liver disease has become an increasingly common 
indication for liver transplantation in the Nordic countries 
in 1994–2015.30 Notably, the decrease in ALD incidence 
occurred despite the absence of major policy changes or 
price increases during the last few decades. In fact, 
Denmark saw a 45% tax reduction on alcohol in 2003,31 
and since then, the consumer price index of alcoholic 
beverages has closely followed the overall consumer 
price index,32 meaning that the relative price of alcoholic 
beverages has remained stable since 2003. The correlation 
between national policies and alcohol consumption and 
ALD is currently under scientific scrutiny, but the topic 
has proved complex. A review of 29 studies of policy 
changes from five different countries found a general 
lack of consistent results,9 while a comprehensive review 
commissioned by the UK Department of Health argued 
that the effect of increased taxation on reducing alcohol 
consumption is clear.33 Our study underscores that alcohol 
policy is just one of the many factors that may influence 
national alcohol consumption. In Denmark, in addition to 
the alcohol tax cut in 2003, we have seen a shift in societal 
norms with respect to alcohol consumption during the last 
decades. For instance, it has become more socially unac-
ceptable to drive under the influence of alcohol,34 
a smaller proportion of road traffic accidents are related 
to alcohol,21 and more women report alcohol abstinence 
during early pregnancy.35 National health campaigns with 
the aim of reducing alcohol consumption have been run 
annually by the Danish Health Authority since 1990, but 
whether these campaigns have influenced societal norms is 
unclear.36
The geographic variation of ALD incidence within 
Denmark is high. Though social factors may confound 
the association between ALD incidence and place of resi-
dence, the variation may give an indication of specific 
geographies where better, more targeted public health out-
reach and education interventions might be required and 
may inform clinical service planning.
Regarding hospital care, the national numbers from 
Statistics Denmark (2006–2018) on hospital care for all 
diseases contrast somewhat with the trends observed in 
this study.37,38 First, the numbers of inpatient admissions 
and emergency room visits are nationally stable, but have 
decreased for patients with ALD. Second, outpatient treat-
ment has increased nationally, while outpatient treatment 
for ALD is stable. Therefore, the trends in hospital care for 
patients with ALD cannot exclusively be explained by 
national tendencies.
We found a decrease in all-cause mortality for all ALD 
patients, as we have previously found for patients with 
ALD cirrhosis alone after adjusting for several 
confounders.12 Our findings are also compatible with the 
results from other countries. In the United States, the in- 
hospital mortality rate of ALD has decreased between 
2005–2014,39 and the mortality rate of ALD cirrhosis has 
decreased between 2004 and 2014.40 The cause of the 
decreased ALD mortality is difficult to ascertain. 
Nevertheless, our data provide a few hints. First, the 
route of diagnosis has changed from a predominantly 
emergent route to a more elective route. Second, the elec-
tive route is associated with a significantly lower mortality, 
which is in line with a prior study on liver cirrhosis 
survival.41 Third, the proportion of 1-year mortality caused 
by ALD has decreased. This suggests that a shift towards 
less severe disease at the time of diagnosis has occurred, 
and the improved overall prognosis is at least in part 
explained by earlier diagnosis. Despite the improved prog-
nosis, the mortality associated with ALD is still very high, 
and the fact that over two-thirds of patients have end-stage 
liver disease (cirrhosis) at the time of diagnosis tells us 
that there is further potential to reduce the overall mortal-
ity by earlier intervention. We have previously found that 
40% of patients who are diagnosed with ALD cirrhosis 
have at least one prior hospital contact with alcohol pro-
blems (alcohol intoxication, harmful alcohol use, or alco-
hol dependence) within a 10-year period25 and that the risk 
of ALD cirrhosis increases with the number of these 
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contacts.42 So naturally, hospital contacts with alcohol 
problems are a potential point of early intervention.
In conclusion, we found a decreasing incidence, 
a stable prevalence, and a nearly fivefold geographic var-
iation of ALD in Denmark during the last decade. 
Concurrently, the burden of ALD on hospital care has 
decreased and the prognosis of ALD has improved. The 
decrease in ALD incidence is driven by progressively 
lower incidence rates in people born after 1960 and likely 
reflects societal changes rather than government policies. 
Based on birth cohort trends, we anticipate a further 
decrease in the incidence of ALD. This is good news for 
public health.
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